Cyclophosphamide-Induced Hypokalemia

Risk Factors and Monitoring

• Prolonged kidney replacement therapy in patients with kidney failure can increase the likelihood of hypokalemia with cyclophosphamide, according to Clinical Nutrition 1, 2
• Baseline serum potassium measurement is recommended before initiating cyclophosphamide, and regular monitoring during treatment is suggested, especially with high-dose protocols, as recommended by Arthritis care & research and Arthritis and Rheumatology 3, 4
• More frequent monitoring is necessary when cyclophosphamide is combined with other medications that can affect potassium levels, as stated in Clinical Nutrition 1, 2

Special Considerations

• In patients receiving kidney replacement therapy, dialysis solutions containing potassium should be used to prevent electrolyte disorders, as recommended by Clinical Nutrition 1, 2